During its differentiation in the insect vector to a stage infective for the mammalian host, Trypanosoma cruzi becomes resistant to lysis by the alternative pathway of complement. To elucidate the mechanism of complement evasion, we studied control of complement activation on the surface of the noninfective epimastigote and the infective culture-derived metacyclic trypomastigote stages (CMT) of T. cruzi. It was found that the predominant form of complement component C3 on epimastigotes is C3b, whereas the majority of C3 on CMT is in the form of the hemolytically inactive fragment iC3b, which cannot participate in C5 convertase formation or lead to deposition of the lytic C5b-9 complex. Our results also showed that C3 binds by a covalent ester linkage to surface molecules of different molecular weight in the epimastigote stage and CMT. Binding studies with purified complement components indicated that CMT do not support efficient formation of an alternative pathway C3 convertase. C3b on the parasite surface fails to bind the amplification component, factor B, rather than showing enhanced binding of the control component, factor H. These results identify the biochemical basis for evasion of complement-mediated killing in T. cruzi and reveal a mechanism for developmental regulation of complement activation.
Protozoan parasites have developed a variety of mechanisms to evade the immunologic defense mechanisms of the mammalian host. Thus, vertebrate-stage parasites and infective vector-stage parasites typically resist direct serum killing and can also evade ingestion or intracellular killing by the phagocytic cells of the host. In contrast, most noninfective vector-stage parasites are susceptible to direct lysis by serum and to phagocytosis and destruction by monocytes or macrophages. For example, the epimastigote stage (Epi) of Trypanosoma cruzi, which multiplies in the gut ofthe vector, is efficiently lysed in human serum by means of alternative complement pathway (ACP) activation (1) . In contrast, the infecting metacyclic trypomastigote stage, the amastigote stage (which multiples intracellularly in the vertebrate host), and the disseminating bloodstream trypomastigote form are not lysed when incubated in human serum (1) (2) (3) . The membrane changes that control the transformation of these parasites from activators of the ACP to nonactivators are incompletely understood, as are the molecular interactions of the ACP with the parasite surface of various life-cycle stages.
Activation of the ACP is currently thought to be mediated and regulated by the following mechanisms: continuous low-grade fluid-phase generation of complement component C3b or water-hydrolyzed C3 occurs normally in serum and results in the random deposition of C3b on all particles (4) . The subsequent interaction of this randomly deposited C3b with proteins of the ACP is determined by the nature of the particle surface (5) (6) (7) . On alternative pathway activators, C3b binds factor B in preference to factor H. C3b that bears B cannot interact with the inactivator enzyme, factor I. Rather, B bound to C3b is cleaved by factor D to produce the active enzyme Bb. The complex of C3b-Bb cleaves additional C3, producing C3b, which leads to amplification of C3b deposition on the activator surface. In contrast, on nonactivators, H (rather than B) is more likely to be bound to C3b. The complex of C3b bearing H does not interact with D. Instead, H acts as a co-factor for I in the cleavage of C3b, yielding the inactive fragment iC3b, which cannot participate in further amplification of C3b deposition.
We have studied (8) the interaction ofthe ACP with Epi and with culture-derived infecting metacyclic trypomastigotes (CMT) (9) . Our results showed that 5-fold more C3 is deposited on Epi than on CMT when these parasites are incubated in normal human serum. Furthermore, GP72, a major developmentally regulated surface glycoprotein, is the preferential site for C3b binding (C3 acceptor) on Epi, but despite its presence it is a poor acceptor for C3 binding on CMT. Since the environment in which C3b is deposited influences its interaction with other complement proteins, the difference in extent of C3 deposition and in the C3 acceptor on Epi and CMT suggests that C3b molecules may be metabolized differently on these life-cycle stages.
In this paper, we have examined the structure of C3 on both Epi and CMT, as well as the mechanism by which alternative pathway convertase formation is controlled in these two life-cycle stages. Our results show that CMT do not support efficient formation of an alternative pathway C3 convertase because CMT fail to bind factor B. Unexpectedly, both Epi and CMT bind the control component factor H with high affinity.
MATERIALS AND METHODS
Buffers and Reagents. The following buffers were used in these experiments: Hanks' balanced salts solution containing 0.15 mM CaCl2, 1.0 mM MgCl2, and 2 mg of human serum albumin per ml (HBSS++-A); lysis buffer, containing 0.05 M Tris (pH 8.2), 100 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.05% sodium azide; lysis buffer containing 1 M NH2OH (pH 10.5); and isotonic Veronal-buffered saline containing 4 mM MgCl2 and 2 mg of human serum albumin per ml (VBS+-A).
T. cruzi Strains and Clones. The Tulahuen strain, the WA250 clone, and the Miranda 88 clone of T. cruzi (M88) were obtained from J. Dvorak (National Institutes of Health, Bethesda, MD). The Epi of these isolates were maintained by serial passage in liver-infusion tryptose broth, as described (8) . CMT ofthe M88 clone were produced with a modification of Sullivan's method (9) Form of C3 on Epi and CMT During Incubation in Serum. Epi of the Tulahuen strain and the WA-250 and M88 clones and CMT of the M88 clone were incubated for 60 min at 370C at a concentration of 5 x 107 parasites per ml in 20% C8-deficient serum in HBSS++-A containing 125I-C3. At various times, aliquots were removed and washed three times in HBSS++-A. The washed pellets were solubilized in 1% NaDodSO4 at 100°C for 5 min. The detergent-soluble supernatant (which contained >90% of the bound 125I-C3) was collected after a 5-min centrifugation at 12,500 x g and was then diluted 1:20 with 1 M NH2OH (pH 10.5) in lysis buffer to cleave the covalent ester linkage between the C3 and acceptor molecules (8, 14) . The resultant mixture was processed as described (15) and C3 fragments were analyzed by 10% NaDodSO4/polyacrylamide gel electrophoresis and autoradiography.
C9 Binding to Epi and CMT. Binding of C9 to Epi and CMT was measured during incubation in 20% PNHS in HBSS+ -A containing 125I-C9, using the reaction conditions described (8) . For experiments in which the molecular form of deposited C3 was to be examined, 100 ,g of 1251-C3 was used instead of [3H]C3 during the second amplification step.
Binding of 125I-B and '2sI-H to Epi-and CMT-Bearing C3b.
Complement component C3b was deposited on Epi and CMT by using sequential cycles of amplification with B and D and C3, as described above. The Epi and the CMT, both bearing C3b, were incubated for 20 min at 30°C at 5 x 106 per ml with dilutions of either 125I-B or 125I-H in VBS+-A. The number of bound molecules was then determined as described (8) . (19) . Cleavage of C3 to C3b results in cleavage of the a chain to a 110-kDa a' chain, which binds covalently to particle surfaces. Further cleavage of the a' chain to 68-and 46-kDa fragments produces iC3b,.
On three different strains of T. cruzi Epi, all of which activate the ACP, the predominant form of C3 observed after serum incubation was C3b containing the 110-kDa a'-chain fragment and the 75-kDa 3 chain (Fig. 1) . Also Parasites at 5 x 10' per ml were incubated for 60 min in 10o, 20%o, or 40%o PNHS containing _251-C9. Molecules of C9 bound per parasite were determined as described (8) . Results shown are mean ± SD for two experiments, each done in duplicate.
Deposition of C3b on Epi and CMT with Purified B, D, and C3. We next pursued the biochemical basis for the difference in C3 fragmentation on Epi and CMT. This was approached by examining how the C3b on the parasite surface interacts with B and H. To prevent C3b from converting to iC3b when the molecule is deposited on Epi and CMT, we used purified amplification proteins of the alternative pathway in the absence of the inactivating proteins H and I. This procedure permits the deposition of C3b on both activators and nonactivators of the alternative pathway since regulation of amplification by conversion of C3b to iC3b cannot occur. The initial deposition of C3 on the parasite surface was accomplished with a fluid-phase alternative pathway convertase; further C3 binding was attained with two sequential cycles of amplification. Initial deposition of C3b on the surface of Epi and CMT was equivalent, consistent with the random deposition of fluid-phase-generated C3b on the parasite surface ( Table 2) . In subsequent cycles, more C3b was deposited on Epi than on CMT, with the result that after the third cycle, 2½2-to 4-fold more C3b was deposited on Epi than on CMT. Furthermore, increases in C3b deposition with each cycle were less for CMT than for Epi. These results suggest that C3 convertase formation is less efficient on CMT than on Epi.
Nature of the Bond and Stability of C3b on Epi and CMT.
Before continuing with the investigation of the interaction of C3b on the parasite surface with B and H, we examined some characteristics of the C3b deposited with the purified alternative pathway proteins. First, we showed that the C3b deposited both on Epi and on CMT was attached by a covalent ester bond to parasite molecules, as indicated by the retarded migration of the a' chain of C3b on NaDodSO4/ PAGE and by hydroxylamine release of the a' chain from its acceptor molecule (Fig. 2) only for CMT at 3 hr). The bands migrating at -280 kDa (the origin of the gel) in the Epi lanes and the non-hydroxylaminetreated CMT samples represent either a' chain that is ester linked to a large parasite acceptor molecule or aggregated C3 that dissociates with hydroxylamine treatment.
Binding of 21SI-H and '25I-B to C3b-Bearing Epi and CMT.
We next examined the interaction of purified radiolabeled B and H with parasite-bound C3b. Saturation binding studies of '25I-B and 125I-H were performed along with ligand binding analyses to determine the affinity of B and H for C3b and the maximum number of B and H binding sites per C3b residue (Fig. 3 ). For Epi (Fig. 3A) , the linear curve for B binding indicated that there was a single population of B binding sites, whereas H binding was most consistent with two classes of H binding sites (dashed lines). The single class of B binding sites was oflower affinity than the high-affinity H binding site (represented by the steep line), but the average B affinity for C3b was higher than the low-affinity H binding site (represented by the shallow line). It is apparent from inspection of the x intercepts that the number of B binding sites with an affinity exceeding that of H binding sites was substantial, although both B and H recognized the majority ofbound C3b. Thus, on Epi, alternative pathway activation occurred be- 
DISCUSSION
Results from this study show that infective culture derived metacyclic trypomastigotes of T. cruzi do not support efficient formation of an alternative pathway C3 convertase, because they fail to bind the alternative pathway amplification component, factor B. In contrast, they bind the control component, factor H, with high affinity. As a consequence, the majority of C3 on CMT is cleaved, producing the hemolytically inactive fragment iC3b, which cannot participate in formation of a C5 convertase or lead to CSb-9 deposition. This conclusion is evidenced by the deposition of fewer C9 molecules (by a factor of 4-6) on CMT than on Epi. We have also found (M. T. Rimoldi and K.J., unpublished observations) that less C3 and C9 (by a factor of [6] [7] [8] (23) (24) (25) (26) (27) . Preliminary evidence exists supporting each of these possibilities. Structural studies indicate that GP72 is altered in CMT compared to Epi (8) , and that new surface-exposed glycoproteins appear in CMT during metacyclogenesis (28, 36) . In addition, data in Fig. 2 suggest that the major C3 acceptor in CMT is a molecule of 25-30 kDa, whereas the C3 acceptor in Epi is GP72 (8) .
Finally, recent experiments in our laboratory suggest that CMT contain a molecule capable of accelerating decay of the alternative pathway C3 convertase. Regardless, the capacity of protease and endoglycosidase treatment to render CMT susceptible to complement lysis and to increase total C3 deposition and the fraction of C3b molecules on the parasite surface (36) suggests that control is exerted by a cell-surface glycoprotein.
A variety of mechanisms are described for evasion of complement-mediated killing by microorganisms and nucleated cells. Complement resistance may result from inefficient complement activation, from a block in the cascade after initiation of the sequence but before C5b-9 formation, or from internalization or shedding of the fully formed C5b-9 complex (29) (30) (31) . In some circumstances, a CSb-9 complex forms and remains stably attached on the cell membrane without causing lethal damage, either because the complex is not deposited at lethal sites or because the metabolic pathways of the cell compensate for ion flux through the C5b-9 channel (32). In T. cruzi, our results show that inefficient activation is a primary means of complement resistance for CMT. However, we cannot exclude an additional mechanism ofresistance, such as deposition of C5b-9 on locations that are ineffective for parasite lysis.
Other protozoa (Leishmania and African trypanosomes) become resistant to ACP lysis during differentiation to infective stages (33, 34) . The infective or vertebrate stage can often be rendered susceptible to ACP lysis by protease treatment (2, 35) , implying that an additional molecule that abrogates effective ACP activation has been removed. This hypothesis has yet to be formally proven and the question of whether B binding regulation is a general mechanism for complement evasion remains to be investigated.
